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1. Introduction 
1.1 Transplant immunology and mechanisms of allograft rejection 
1.1.1 Central role of T lymphocytes 
Although many cells can participate in the process of transplant rejection, only T 
lymphocytes appear to be absolutely required (Krensky et al., 1990).  Mice with 
genetic or induced T-cell deficiency cannot reject grafts because they lack the cellular 
mechanisms to recognize an antigen as foreign (Sayegh and Turka, 1998).  
Nature T cells express either the CD4 or the CD8 glycoprotein on their surface.  
The CD4 T cell, so-called helper T cell (Th cell), plays a critical role in both the 
initiation and the coordination of the rejection response (Krieger et al., 1996). The 
recipient mounts a rejection response following CD4 T cell recognition of foreign 
antigens derived from the allograft. These antigens are encoded predominantly by 
highly polymorphic loci within the major histocompatibility complex (MHC), which 
in human is known as the human leucocyte antigen (HLA) complex, located on the 
short arm of chromosome 6 (Krensky, 2000).  Foreign MHC molecules are presented 
by both the direct and the indirect pathways to host T cells (Fig.1.1) (Denton et al., 
1999).  In the direct pathway, recipient T cells recognize intact allogeneic MHC 
(foreign MHC) molecules expressed on donor cells.  In the indirect pathway, 
recipient antigen-presenting cells (APCs) process donor antigens intracellularly and 
present donor MHC-derived peptides on recipient MHC class II molecules to T cells, 
initiating the alloimmune response. The direct pathway may be responsible for the 
vigorous immune response in acute rejection, whereas indirect allorecognition may 
have the dominant role in chronic rejection. 
A novel ‘third pathway’ of antigen presentation has been proposed, namely direct 
presentation of intact donor MHC by host APCs (Vongwiwatana et al., 2003). In this 
pathway, host APCs acquire membrane fragments from donor cells containing intact 
donor MHC molecules. These may then be presented to host T cells and/or B cells to 
generate an immune response. This pathway could provide the explanation for how 
recipient APCs can prime cytotoxic T lymphocytes (CTL) to react against intact donor 
MHC molecules (e.g. on epithelium), as these cells cannot be primed by the indirect 
 1
pathway. 
 
Figure 1.1  Pathways of Recognition of Allogeneic MHC Molecules and Mechanisms of 
Graft Rejection. Graft rejection is usually initiated by CD4 Th cell that bind peptides in 
complexes with MHC class II molecules on antigen-presenting cells. In the direct pathway of 
recognition, an MHC molecule on a foreign (allogeneic) cell, such as an antigen-presenting cell 
(allogeneic APCs), binds to the Th cell. In the indirect pathway, the foreign MHC molecule is 
processed into peptides that are presented to the Th cell by one of the body’s own 
antigen-presenting cells (self APCs). In either case, activated CD4 Th cells proliferate and secrete 
a variety of cytokines that serve as growth and activation factors for CD8 T cells (CTL), B cells, 
and macrophages, which cause destruction of the graft by direct lysis of target cells, antibody 
production, and delayed-type hypersensitivity mechanisms, respectively. 
 
Full activation of T cells requires two distinct but synergistic signals (Janeway, Jr. 
and Bottomly, 1994).  Antigen recognition alone is insufficient to activate fully the 
CD4 T cell; a second (costimulatory) signal must be provided by cognate ligands on 
the antigen-presenting cell. When both signals are provided, the T cell secretes 
optimum concentrations of interleukin-2 (IL-2) and other cytokines, thus permitting 
the development of an expanded population of mature effector cells (T cells, B cells, 
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and macrophages) capable of mediating a sustained immune response. In the absence 
of the second signal, the CD4 T cell becomes unresponsive to further exposure to 
antigen, fails to secrete cytokines, and may undergo programmed cell death 
(apoptosis).  The best-characterized co-stimulatory signal is provided by ligation of 
CD28 on the surface of the CD4 T cell with a member of the B7 family of molecules 
(B7-1 or B7-2) on the APCs (Krensky, 2000). CD40-CD154 interactions provide 
another important co-stimulatory pathway between activated T cells, B cells, APCs 
and endothelial cells (Figure 1.2). CD40-CD154 interaction plays an important role 
not only in acute graft rejection but also in chronic rejection (Kishimoto et al., 2000). 
The combined blockade of the CD40-CD154 and CD28-B7 pathways has been shown 
to be particularly effective in allo- (Larsen et al., 1996) as well as xeno-transplant 
models (Elwood et al., 1998).  Moreover, this combination therapy induced long 
term rejection free renal allograft survival in non-human primates (Kirk et al., 1997). 
Several ‘novel’ co-stimulatory molecules were described recently (Sharpe and 
Freeman, 2002; Coyle and Gutierrez-Ramos, 2001; Yamada et al., 2002; Salama and 
Sayegh, 2003). Structurally, the novel co-stimulatory molecules are related either to 
CD28-B7 or to CD40-CD154.  They differ in the timing and distribution of their 
expression and in delivery of positive or negative signals to T cell and B cells; they 
have both overlapping and distinct roles. The novel co-stimulatory molecules 
differentially affect proliferation, differentiation, survival, and functional repertoire. 
Thus, the initial notion that co-stimulatory molecules play a stimulatory role required 
for prevention of anergy has had to undergo revision. Indeed, it is the integration of 
positive and negative co-stimulatory signals that ultimately determines the outcome of 
the T-cell response (Rothstein and Sayegh, 2003).  
Alloactivated CD4 T cells subsequently interact with effector cells of the rejection 
response via direct cell-cell contact and cytokine secretion. By an increase in the 
activation and function of B cells, CTL and monocyte/macrophages, alloactivated 
CD4 T cells promote alloantibody production, antigen-specific cell lysis, and delayed 
type hypersensitivity responses, respectively. These effector mechanisms ultimately 
result in graft destruction.  
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Figure 1.2  Costimulatory pathways for T-cell activation. Dendritic cells constitutively 
express B7 and CD40 cell surface molecules. Specific triggering of the T-cell receptor (TCR) on 
naive T cells occurs in the context of co-stimulatory signals via B7→CD28 engagement leads to 
T-cell activation. In a second step, activated T cells express CD154 (CD40 ligand, CD40L) on 
their cell surface. Interaction of CD40 on the APCs and CD154 on the T cell activates IL-12 
production by the APCs.  
 
 
Following the interaction of TCR and co-stimulatory molecules with their 
respective ligands, T-cell activation begins. Various kinases are activated at or near 
the cell surface and intracellular calcium levels rise. These events then activate signal 
transduction cascades which result in the transcription of new genes in the nucleus. As 
new genes are expressed, the T cell divides (proliferates) and differentiates. In parallel, 
a calcium-dependent pathway involving the phosphatase calcineurin provides access 
for cytoplasmic components of the nuclear factor of activated T cells, NFAT, to enter 
the nucleus. These factors bind in a combinatorial fashion to promoters/enhancers of 
T lymphocytes and result in transcription of new gene products. Transcription of IL-2, 
a T-cell growth factor, is well characterized and is important in understanding the 
mechanism of action of the widely used immunosuppressive drugs such as 
cyclosporine (CsA) and tacrolimus (Tac).  
Extensive data from animal studies indicate that alloantigen-actived T cells play a 
key role in initiating the process of chronic rejection. It is hypothesized that activated 
CD4 T cells produce key cytokines which activate macrophages and B cells. 
Chemoattractants further recruit circulating mononuclear cells to the graft, which 
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along with endothelial cells, secrete growth factors that cause smooth muscle cell 
proliferation leading to vascular intimal occlusion and interstitial fibrosis (Womer et 
al., 2000) 
1.1.2 B lymphocytes 
  B-cell responses against membrane MHC antigens begin with MHC binding to the 
B-cell receptor (BCR) of alloreactive B Cells, leading to activation as well as antigen 
uptake and processing. MHC molecules are generally found on the membrane of 
donor cells, but they can also be released as a soluble protein or on membrane vesicles. 
B-cell activation will not lead, however, to an effective antibody response unless help 
is provided by Th cells (Vongwiwatana et al., 2003). 
As well as initiating signal transduction cascades, BCR crosslinking will also lead 
to internalization of the antigen. Antigen bound by B cells is internalized and 
processed into peptides to be presented on MHC class II molecules on the surface. 
MHC class II is expressed on the surface along with co-stimulatory molecules 
important in the function of B cells as APCs. Recognition of the presented peptide by 
a Th cell leads to a conjugate between the two cells (Figure 1.2). Cytokines are 
released from the Th cell, and interactions between co-stimulatory molecules allow 
for clonal expansion, diversification, and affinity maturation of the responding B cells. 
Following affinity maturation, B cells expressing antibodies with high affinity for the 
specified antigen can become memory B cells or antibody-producing plasma cells.  
When a T cell finds an antigen-specific B-cell match, it will provide the required 
cytokines and co-stimulatory signals for antibody production. Antigen-activated B 
cells express B7 and CD40 and activated T cells express CD154. CD40-CD154 
interactions are required for effective antibody responses (Figure 1.2).  
 
1.2 Immunosuppressive therapy in solid organ transplantation 
1.2.1 Mechanisms of action of immunosuppressive drugs 
  During the past 50 years, many immunosuppressive drugs have been described. 
These drugs now used fall into five groups with different mechanisms of action 
(Allison, 2000). a) Regulation of gene expression. The classical examples are the 
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glucocorticoids, which directly or indirectly regulate the expression of many genes. b) 
Alkylation agents.  An example is cyclophosphamide. c) Kinase and phosphatase 
inhibitors. CsA and Tac not only inhibit the phosphatase activity of calcineurin (they 
are also considered calcineurin inhibitors) but also the JNK and p38 cascades linked 
to the T-cell receptor (Matsuda and Koyasu, 2000).  Rapamycin inhibits a kinase 
cascade.  d) Inhibition of de novo purine synthesis. The first generation included 
azathioprine (AZA), which effects are broad rather than selective (Allison, 2000). The 
second generation included mycophenolate mofetil (MMF).  e) Inhibition of de novo 
pyrimidine synthesis. For example, leflunomide can suppress lymphocyte 
proliferation by inhibition of dihydrorotate dehydrogenase.  
  CsA, Tac and MMF are discussed in detail here. 
 
1.2.1.1 Mechanism of action of cyclosporine (CsA) 
CsA, a neutral lipophilic cyclic undecapeptide isolated from the fungus 
Hypocladium inflatum gams, has been widely used for the treatment of allograft 
rejection since Borel et al (Borel et al., 1976) reported its immunosuppressive activity. 
In the cytoplasm, CsA binds to its immunophilin, cyclophylin (CpN), forming a 
complex between cyclosporine and CpN. The cyclosporine–CpN complex binds and 
blocks the function of the enzyme calcineurin (CaN), which has a serine-threonine 
phosphatase activity. Inhibition of the action of calcineurin results in a complete block 
in the translocation of the cytosolic component of the NFAT, resulting in a failure to 
activate the genes regulated by the NFAT transcription factor (Figure 1.3). These 
genes include those necessary for T-cell proliferation such as IL-2, for the activation 
of macrophages such as interferon gamma (IFN-γ), as well as those required for 
B-cell help such as IL-4 and CD-154 (Ho et al., 1996).   
 
1.2.1.2 Mechanism of action of tacrolimus (Tac) 
Tac, the macrolide product of the bacterium Streptomyces tsukubaensis, inhibits 
IL-2 production by T cells in a fashion that is similar to that of CsA. After Tac forms 
a complex with FK-binding proteins (FKBP), the complex inhibits the phosphatase 
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activity of calcineurin (Figure 1.3), thereby blocking the activity of the cytoplasmic 
component of NFAT (Fung, 2004). 
 
Figure 1.3 Mechanism of action of CsA or Tac (FK506) 
 
 
1.2.1.3 Mechanism of action of Mycophenolate mofetil (MMF) 
  MMF is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine 
monophosphate dehydrogenase (IMPDH). This is the rate-limiting enzyme in de novo 
synthesis of guanosine nucleotides (Figure 1.4). T- and B-lymphocytes are more 
dependent on this pathway than other cell types. Moreover, MPA is a fivefold more 
potent inhibitor of the type II isoform of IMPDH, which is expressed in activated 
lymphocytes, than of the type I isoform of IMPDH, which is expressed in most cell 
types. MPA has therefore a more potent cytostatic effect on lymphocytes than on 
other cell types. IMPDH type II enzyme knocked out mouse demonstrate significantly 
decreased lymphocyte responsiveness to stimulation with anti-CD3 and anti-CD28 
antibodies indicating that a moderate decrease in the ability of murine lymphocytes to 
synthesize guanine nucleotides during stimulation results in significant impairment in 
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T-cell activation and function (Gu et al., 2000). In liver, MMF is converted by ester 
hydrolysis to its active metabolite, MPA, which non-competitively and reversibly 
inhibits the activity of IMPDH during DNA synthesis in the S phase of the cell cycle. 
This is the principal mechanism by which MPA exerts immunosuppressive effects 
(Allison and Eugui, 2000). MPA can also induce apoptosis of activated 
T-lymphocytes, which may eliminate clones of cells responding to antigenic 
stimulation.  
 
 
Figure 1.4. Mechanism of action of mycophenolate moletil 
 
1.2.2 Immunosuppressive agents in clinical transplantation 
  The goal of immunosuppression in solid organ transplantation is to blunt the 
immune response of the patient to the allograft, while maintaining sufficient 
resistance to avoid opportunistic infections and malignancy. Despite progress in this 
field, rejection processes, particularly of the chronic form, remain an important cause 
of morbidity and graft loss (Kilic and Kahan, 2000). 
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  Because most of new immunosuppressants differ in their mechanisms of action, 
and because the toxicities are mechanism-based, the wide array of new drugs offers 
the opportunity to use combinations that block different pathways of immune 
activation while at the same time selecting combinations with non-overlapping 
toxicity profiles so that doses of each drug can be reduced below toxic levels 
(Gummert et al., 1999b). 
 
1.2.2.1 Application of calcineurin inhibitors (CNI) in clinical transplantation and 
their side effects 
  CNI are currently the most of used immunosuppressive regimens in clinical organ 
transplantation. CNI prevents IL-2 gene transcription, thereby inhibiting T cell IL-2 
production. The introduction of CsA proved an important advance in 
immunosuppressive therapy and increased 1-year graft survival for cadaveric kidney 
allografts by 10%. In maintenance immunosuppression therapy, CsA was the 
most-used CNI in solid organ transplantation until the introduction of Tac around 
1994 (Kaufman et al., 2004). A switch from CsA to Tac occurred for transplants 
performed in 1995 for liver and in 2001 for kidney.  The reasons for this conversion 
are most likely related to multicenter trial data that have suggested lower rates of 
acute rejection and lower rates of steroid resistant rejection associated with Tac 
(Johnson et al., 2000; Pirsch et al., 1997). Tac is widely used in liver transplantation, 
in which its greater water solubility and lesser dependence on bile salt absorption 
results in improved bioavailability over CsA (Denton et al., 1999). Both drugs can 
cause multiple non-immunological adverse events. The most common side-effect of 
CNI is nephrotoxicity (Klintmalm and Gonwa, 1995; Morales et al., 2001; Mor et al., 
1994) although the progression of renal insufficiency after liver transplantation is 
slow (Braun et al., 2003). The incidence of end-stage renal disease requiring renal 
replacement therapy ranges between 0.8% and 9.5% after liver transplantation 
(Gonwa et al., 1991; Platz et al., 1994; Gonwa et al., 2001). Another study shows that 
by 13 years after liver transplantation, patients with end-stage renal disease had a 
28.2% survival rate compared with 54.6% of the recipients that did not develop 
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end-stage renal disease (Gonwa et al., 2001). The other side effects include 
neurological disorders, arterial hypertension and metabolic disorders (Rabkin et al., 
2002). Recent studies have also increased the understanding of mechanisms by which 
the nephrotoxicity and other side effects of CsA are mediated.  Hemodynamic effects 
of CsA include reversible, dose-related renal vasoconstriction with reduced 
glomerular filtration rate and systemic hypertension. Endothelin-1 (ET-1) has been 
implicated in these effects. CsA has been shown to augment the action of 
endothelin-converting enzyme, and the production of ET-1, by endothelial cells. ET-1 
is also believed to contribute to transplant vasculopathy and chronic rejection. CsA 
treatment can also lead to tubular interstitial fibrosis in the kidney, an effect associated 
with increased expression of transforming growth factor-β (TGF-β) (Han et al., 1995). 
CsA can increase the expression of pro-apoptotic genes in the kidney (p53, Bax, Fal-L) 
and decrease the expression of the survival gene Bcl-2.  This is one mechanism 
leading to drop-out of tubular cells.  Tac has shown efficacy similar to that of CsA, 
but also the nephrotoxicity and some other side effects of CsA (Allison, 2000). 
  For these undesirable effects immunosuppressive alternatives to CNI drugs have 
begun to emerge during the past few years (Flechner, 2003). Minimizing CNI drugs 
has been considered at various time points post-transplant, and can be described in 
several ways. The recent introduction of the potent immunosuppressive agent such as 
MMF represents an opportunity to develop a regimen designed to minimize 
drug-induced nephrotoxicity (Flechner, 2003).  
 
1.2.2.2 MMF and immunosuppressive drug combinations in solid transplantation 
  As an immunosuppressive agent, MMF was introduced in 1982 and now approved 
for use in many countries to prevent allograft rejection and to treat ongoing rejection 
(Allison and Eugui, 2000; Mele and Halloran, 2000). MMF has become an important 
therapeutic tool in the transplant field.  Randomized clinical trials have shown that 
MMF, when used with CsA and steroids, reduces the frequency and severity of acute 
rejection episodes in kidney and heart transplants, improves patient and graft survival 
in heart allograft recipients and increases renal allograft survival at 3 years (Mele and 
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Halloran, 2000). It has also been effective in reversing acute and resistant rejection 
episodes in heart, kidney and liver recipients.  The ability of MMF to facilitate 
sparing of other immunosuppressive agents, particularly in CsA-related 
nephrotoxicity, is also promising. By permitting reduction in CsA dose, MMF may 
stabilize or improve renal graft function in patients with CsA-related nephrotoxicity 
or chronic allograft nephropathy.  MMF also shows more immunosuppressive 
potency than AZA, another purine synthesis inhibitor used in clinic (Fischer et al., 
2000; Taylor et al., 1999; Vincenti, 2004). 
  In renal transplantation, CsA withdrawal was associated with a significant risk of 
acute rejection and subsequent chronic rejection (Offermann, 2004; Smak Gregoor et 
al., 2002). Evidence has accumulated that MMF, administered to human organ graft 
recipients alone or with a low dose of CNI, can decrease the incidence of acute 
rejection (Triemer et al., 2000) and improve renal function (Houde et al., 2000; 
Francois et al., 2003). MMF may prevent chronic rejection by decreasing the 
recruitment of lymphocytes and monocytes into grafted organs and suppressing the 
proliferation of arterial smooth muscle cells (Allison, 2002). Addition of MMF to a 
CsA-based immunosuppressive regimen also significantly increased the safety of 
steroid withdrawal in clinical study (Hocker et al., 2004). The combination of Tac and 
MMF may be superior to Tac and sirolimus in terms of improved renal function and 
lower risk of hypertension and hyperlipidemia (Vincenti, 2004).  
  In liver transplantation, introduction of MMF as monotherapy resulted in an 
improvement in renal function, even when introduced several years after 
transplantation (Moreno et al., 2003b; Papatheodoridis et al., 1999; Raimondo et al., 
2003; Moreno et al., 2003a). However, some reports demonstrated that the risk of 
acute rejection may increase with an incidence ranging between 18% and 20% (Schlitt 
et al., 2001; Stewart et al., 2001). Only in some selected patients MMF monotherapy 
seems to be safe and allows a significant improvement in renal function 
(Papatheodoridis et al., 1999).   
Recently, the effectiveness and safety of a regimen with combination of minimal 
CsA and standard MMF doses in long-term liver transplant recipients was evaluated 
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(Cantarovich et al., 2003; Koch et al., 2004; Pfitzmann et al., 2002b; Bunchman et al., 
2001) and the results are encouraging (Pfitzmann et al., 2003; Hodge et al., 2002). 
Similar findings were noticed in heart transplant recipients (Baryalei et al., 2003). 
MMF also was found to be effective in controlling ongoing chronic rejection in liver 
allografts under CNI based immunosuppression (Daly et al., 2002; Pfitzmann et al., 
2002a). However, the benefit in renal function still has to be balanced with a risk of 
acute rejection in some patients, although low dose of CNI were remained. Therefore, 
careful follow-up of these patients is mandatory. Future studies should determine 
whether the risk of acute rejection could be minimized by therapeutic drug monitoring 
of immunosuppressive drugs, by other immunosuppressive combinations 
(Cantarovich et al., 2003) or by monitoring the immune status of recipients.  
 
1.3 Immunologic monitoring of human T lymphocyte function 
T lymphocytes play a critical role in the regulation of immune responses, and are 
responsible for mediating many of the effector mechanisms of the immune system. 
For this reason, there has always been a need for assays to measure accurately the 
activity of populations of T cells. Assessing the quantitative and qualitative nature of a 
T cell response following immunosuppressive therapy can provide valuable 
information about the efficacy of a treatment, in place of a clinical endpoint. The 
measurement of blood concentrations of immunosuppressants provides only an 
indirect evaluation of the degree of immunosuppression attained in an individual 
patient (Yatscoff et al., 1998; Dambrin et al., 2000). When combined treatments are 
used the biological impact may be higher than that predicted by the individual blood 
concentrations of each immunosuppressant. Thus the measurement of several markers 
has been proposed to assess the impact of immunosuppressants on the immune 
systems of individual patients (Millan et al., 2003). 
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1.3.1 Lymphocyte proliferation assays using carboxfluorescein diacetate 
succinimidyl ester (CFSE) 
  The measurement of the proliferation of lymphocytes that occurs following stimuli 
is a fundamental technique for assaying T-cell responses. Over 30 years, 
antigen-specific lymphocyte proliferation has been measured by the incorporation of 
3H-thymidine into the DNA of cells in S phase by pulsing for 6-18 h at the end of an 
in vitro culture period (Piguet and Vassalli, 1973). The level of 3H-thymidine 
incorporation correlates directly with the number of cells that synthesis DNA during 
the pulse period. Although incorporation of 3H-thymidine provides a good correlated 
of T-cell division, the 3H-thymidine assay does not provide any information on the 
phenotype of the proliferating cells in heterogeneous cell populations such as PBMC 
(Mannering et al., 2003). Furthermore, because 3H-thymidine incorporation measures 
DNA synthesis during a short pulse at the end of a 3-7-day culture period, the fate of 
cells that have proliferated cannot be determined. It is well known that proliferation in 
response to antigen is followed by a wave of apoptosis (Renno et al., 1999; 
Mannering et al., 2002; Marin et al., 2003).  T cells that exhibit a vigorous response 
by 3H-thymidine incorporation may be destined to die by apoptosis a few days later. 
Hence, the response measured by 3H-thymidine may overestimate the magnitude of 
the T-cell response, by assaying at the peak of DNA synthesis (Mannering et al., 
2003).  
The technique for analyzing cell division using serial dilution of the 
fluorescein-based dye CFSE was introduced in 1994 by Lyons and Parish (Lyons, 
1999) and has become widely used around the world for investigating cell 
division-linked differentiation of lymphocytes and for the investigation of kinetics of 
proliferation during immune responses (Lyons, 1999).  CFSE consists of a 
fluorescein molecule containing two acetate moieties and a succinimidyl ester 
functional group.  In this form, it is membrane permeant and non-fluorescent. After 
diffusion into the intracellular environment, endogenous esterases remove the acetate 
groups, rendering the molecule highly fluorescent and non-permeant to the cell 
membrane. Cell division can be tracked by detecting the progressive halving of the 
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fluorescence intensity of the dye in cells after each division (Parish, 1999). It can be 
used both in vitro and in vivo, allowing 8 to 10 successive divisions to be resolved by 
flow cytometry. One of the major advantages of the CFSE division technique is that 
dividing cells can be identified in complex mixtures by immunophenotyping with 
appropriately conjugated monoclonal antibodies (Lyons, 2000). 
 
1.3.2 Analysis of expression of activation surface markers of T cells by flow 
cytometry 
  Analysis of the expression of activation markers on the surface of T cells by flow 
cytometry has also been investigated as a method for evaluating T cell proliferation 
and function. Cell surface markers (molecules) that have been used include: CD25, 
CD69, CD71, CD154 and HLA-DR (a subtype of human MHC class II molecule), all 
of which are upregulated following T cell activation.   
 
1.3.3 Measurement of cytokine production by T cells 
  Th cells can be subdivided into Th1 and Th2 populations, based on the types of 
cytokines that are produced following antigen-induced activation. Th1 cells and the 
pathway they dominate are heavily reliant on IFN-γ, and to a lesser extent IL-2. Th2 
cells are most heavily reliant on IL-4 and sometimes IL-5. It can be valuable to know 
the relative proportions of these two populations of cells that are circulating in vivo 
during immunosuppressive therapy.  Cytokine levels in body fluids can be measured 
directly; alternatively, populations of T cells can be stimulated and cultured in vitro, 
and the quantities of cytokines that are produced can be determined. 
 
1.3.3.1 Assessment of cytokine production by flow cytometry 
  The most simply means to estimate Th1 and Th2 T-cell responses at the level of 
total cell population are to culture PBMCs or T cells in vitro in the presence of the 
appropriate antigen or stimulus. After a specified period of time, the supernatant from 
these cultures is removed for testing and assayed for the presence of cytokines, that 
are indicative of the Th1 and Th2 subsets respectively, using an immunoassay such as 
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enzyme-linked immunosorbent assay (ELISA). The cytometric Bead Array (CBA) 
from BD Pharmingen is a flow cytometric-based assay for the detection of cytokines 
from cell supernatants or serum samples. Each bead in a CBA provides a capture 
surface for a specific protein and is analogous to an individually coated well in an 
ELISA plate. The advantage of using the CBA assay is that it is an accurate and 
sensitive method for measuring 6 to 8 kinds of cytokine levels at one time. In addition, 
it requires small volumes for analysis. 
 
1.3.3.2 Measurement of cytokine mRNA expression by real-time RT PCR 
  Assaying cytokine production at the level of the total cell population has the 
advantage that the cytokines are produced in measurable amounts.  However, the 
amount of cytokine measured might not accurately reflect the total quantity of 
cytokine produced, because some of the cytokine might have bound to, and been 
‘used up’ by cells that are present in the culture.  One solution to this problem is to 
measure cytokine messenger RNA (mRNA) levels, which can be done quantitatively 
using competitive polymerase chain reaction (PCR) assays. The interest in a 
quantitative detection of cytokine mRNA profiles has increased substantially in recent 
years (Hartel et al., 2001).   
  Real-time quantitative reverse transcriptase PCR (RT-PCR), which is the latest 
innovation in the field of PCR technology, is becoming widely used and provides a 
sensitive, reproducible, and accurate method for determining mRNA cytokine levels 
in tissues or cells (Giulietti et al., 2001; Overbergh et al., 2003). This method is based 
on the detection of a fluorescent signal produced and monitored during the 
amplification process, without the need for post-PCR processing.  
   
1.4 Aim of this work 
The increasing number of more selective immunosuppressive agents available for 
organ transplantation has the potential to be of great benefit. Typically, newer agents 
are used as adjuncts in a regimen based on corticosteroids and either CsA or Tac. The 
initial trials of agents such as MMF and sirolimus showed clinical efficacy when used 
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as adjuncts. However, limited data are available about the changes of immunological 
function after alternative treatment strategy. It is difficult to optimize the regimens in 
general or for specific subgroups using large clinical trials with outcome endpoints for 
each of the many possible combinations. In particular, it is unclear whether it is 
preferable to maximize the dose of one agent (e.g. CNI), or to add a second agent (e.g. 
MMF) to a moderate dose of the first agent to optimize immunosuppression. Lower 
doses of multiple agents may minimize side effects associated with any single agent. 
A surrogate method of measuring immunosuppressive effects in patients and in vitro 
is desirable to determine the response to new agents and to prevent the complications 
of over- or under-immunosuppression (Ogawa et al., 2001). 
Therefore, in this study, we investigated the impact of combined MMF and low 
dose of CNI therapy on T cell function in vivo and in vitro.  
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2.  Materials and methods 
2.1 Materials 
Immunosuppressive agents 
Mycophenolic acid  (MPA)  (Roche Bioscience, USA)  
CsA  (LC Laboratories, USA, Cat. No.C-6000) 
Tac (FK506)  (LC Laboratories, USA, Cat. No.F-4900) 
Reagents for PBMC isolation and culture 
Ficoll Separating Solution  (Biochrom AG, Germany, Cat.No. L6115) 
RPMI 1640  (PAA Laboratories, Austria, Cat. No. E15-039) 
L-glutamine  (PAA Laboratories, Austria, Cat. No.M11-004) 
Penicillin/Streptomycin 100 x  (PAA Laboratories, Austria, Cat. No. 011-010) 
Fetal bovine serum  (FBS)  (PAA Laboratories, Austria, A15-043) 
Dulbecco’s Phosphate-buffered saline (DPBS)  (PAA Laboratories, Austria, Cat. 
No. H15-002) 
Bovine Serum Albumin Fraction V  (Roche Diagnostics GmbH, Germany, Cat. 
No. 735 078) 
Antibodies for T cell stimulation 
  anti-human CD3   (clone HIT3 a, BD Pharmingen, 555336)  
anti-human CD28  (clone CD28.2, BD Pharmingen, 555725), 
Reagents and kits for cell proliferation and cell cycle assay 
CFSE  (Molecular Probes, USA, Cat. No. C-1157).  
Dimethylsulfoxide (DMSO)  (Sigma Aldrich, Germany, Cat.No. D2650) 
FITC BrdU Flow Kits (BD Pharmingen, Cat. No.559619) 
Cytokine assay kit 
BDTM Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit  (BD 
Pharmingen, 550749) 
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Antibodies for surface antigen analysis 
  Specificity Clone Conjugation Source Cat. No 
CD45RA HI100 FITC BD pharMingen 555488 
CD25 M-A251 FITC BD pharMingen 555431 
CD30 BerH8 FITC BD pharMingen 555829 
CD62L Dreg 56 FITC BD pharMingen 555543 
CD71 M-A712 FITC BD pharMingen 555536 
CD4 RPA-T4 FITC BD pharMingen 555346 
CD14 M5E2 FITC BD pharMingen 555397 
Anti-TCR B1 FITC BD pharMingen 559878 
HLA-DR,DP,DQ TU39 FITC BD pharMingen 555558 
CD3 SK7 FITC BD Biosciences 345764 
CD45RO UCHL1 PE BD pharMingen 555493 
CD28 CD28.2 PE BD pharMingen 555729 
CD38 HIT2 PE BD pharMingen 555460 
CD69 FN50 PE BD pharMingen 555531 
CD154 TRAP1 PE BD pharMingen 555700 
CD80 L307.4 PE BD pharMingen 557227 
CD103 Ber-ACT8 PE BD pharMingen 550260 
CD134 ACT35 PE BD pharMingen 555838 
CD27 M-T271 PE BD pharMingen 555441 
CD56 B159 PE BD pharMingen 555516 
CD122 Mik-b2 PE BD pharMingen 554522 
CD3 UCHT1 PerCP-Cy5.5 BD pharMingen 555334 
CD56 B159 PerCP-Cy5.6 BD pharMingen 555517 
CD8 RPA-T8 APC BD pharMingen 555369 
CD4 RPA-T4 APC BD pharMingen 555349 
CD45 HI30 APC BD pharMingen 555485 
CD95 B159 APC BD pharMingen 558814 
CD19 HIB19 FITC BD pharMingen 555412 
 
 
Chemicals and kit for real time RT-PCR 
  Isopropyl alcohol  (Sigma Aldrich, Germany, Cat. No I-9516) 
  Chloroform  (Sigma Aldrich, Germany, Cat. No. C-2432)  
DEPC-treated water  (Ambion, Germany, Cat. No.9920) 
  Ethanol  (SERVA, Germany, Cat. No.11903) 
  TRIzol Reagent  (Invitrogen, USA, Cat. No.115596-018) 
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  TaqMan One-Step RT-PCR Master Mix Reagents  (Applied Biosystems, USA, 
Cat.No. 4309169) 
 
Stock solution 
10mM CFSE stock solution 
CFSE            25 mg 
DMSO            4.5 mL 
Aliquot and store at -20º C 
1mg/mL Anti-human CD3 antibody stock solution 
Anti-human CD3 antibody       0.5 mg 
Sterile PBS           0.5 mL 
Store at 4º C. 
1mg/mL Anti-human CD28 antibody stock solution 
Anti-human CD28 antibody       0.5 mg 
Sterile PBS           0.5 mL 
Store at 4ºC. 
10mg/mL MPA stock solution 
Mycophenolic acid         10 mg 
DMSO            1.0 mL 
Store at 4 ºC 
50mg/mL CsA stock solution 
CsA            100 mg 
DMSO            2 mL 
Store at -20 ºC 
10mg/mL Tac stock solution 
Tac             10 mg 
DMSO            1 mL 
Store at -20 ºC 
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PBS containing 5% (v/v) heat-inactivated FBS 
DPBS            475 mL 
Heat-inactivated FBS         25 mL 
Culture Medium 
RPMI-1640 supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin , 100 
µg/mL streptomycin and 2 mM L-glutamine. 
 
RPMI-1640 medium         450 mL 
Heat-inactivated FBS         50 mL 
200mM L-glutamine         5 mL 
100 x Penicillin/streptomycin cocktail     5 mL 
Buffers 
Staining/wash buffer: 
PBS            500 mL 
BSA            0.5 g 
10% sodium azide         5 mL 
Store at 4°C 
Fixation buffer for FACS analysis 
PBS            500 mL 
Paraformaldehyde         10 g 
Store at 4°C 
2.2 Monitoring of surface markers of PBMC in liver transplant patients 
2.2.1 Patients 
32 liver transplant recipients (22 male/10 female) under CNI-based 
immunosuppression were enrolled in this prospective study. The patients were divided 
into two groups.  In MMF/CNI reduction group (n=22), MMF dose was increased 
from 2 x 500 mg/day to 2 x 1 g/day; CNI dose was progressively tapered to achieve 
target trough levels of 2-4 ng/mL for Tac and 25-50 ng/mL for CsA.  In the control 
group (n=10), patients maintained their CNI dose.  
Four months after conversion to MMF regimen, blood samples were collected for 
PBMC isolation.  
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2.2.2 PBMC isolation 
  Blood samples were collected from patients in the presence of sodium citrate.  
PBMC were isolated by density separation over Ficoll separating solution (1700 
rpm/30 min).  Mononuclear cells at the interface were collected and washed twice 
with PBS.  
2.2.3 Surface marker staining and flow cytometric analysis 
The PBMCs were resuspended at 1 x 106/mL in staining buffer and labeled with 
antibodies (Table 2.1) for 30 min on ice. Then the cells were washed twice and fixed 
with 2% paraformaldehyde in PBS. The expression of each surface marker was 
measured by FACSCalibur and CellQuest Pro software (BD Biosciences, USA). 
Forward and sideward scatter were used to identify the lymphocyte and monocyte 
gate, and subsequent analysis was performed on this gated set of cells; 100,000 cells 
per sample were counted. Results were analyzed by WinMDI version 2.8 software 
(Joseph Trotter, Scripps Research Institute, La Jolla, CA). 
2.3 T cell function study in vitro 
2.3.1 Isolation of PBMC  
Blood samples were collected from healthy volunteers and the PBMCs were 
isolated as described in 2.2.2. 
2.3.2 Pre-treatment of cells with immunosuppressive drugs 
PBMCs were resuspended in RPMI medium (1 x 106 cells/mL) and divided into 12 
groups. The stock solutions of immunosuppressive drugs were firstly diluted in RPMI 
to have a 310 µM working solution of MPA, 100 µg/mL working solution of CsA and 
10 µg/mL working solution of Tac separately. These working solutions were added to 
each group of PBMCs according Table 2.2. Drugs were allowed to equilibrate at 37 ºC 
for 30 min to ensure homogeneous distribution of all cells. 
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Table 2.1 Combinations of antibodys  
No. FITC PE CY APC 
1 Iso Iso Iso Iso  
2 CD45RA CD45RO CD3 CD8 
3 CD25 CD28 CD3 CD8 
4 CD30 CD38 CD3 CD8 
5 CD62L CD69 CD3 CD8 
6 CD71 CD154 CD3 CD8 
7 CD4 CD80 CD3 CD8 
8 CD14 CD103 CD3 CD8 
9 Anti-TCR (γ/δ) CD134 CD3 CD8 
10 CD45RA CD27 CD3 CD4 
11 HLA-DR,DP,DQ CD154 CD3 CD4 
12 CD25 CD28 CD3 CD4 
13 CD19 CD56 CD3 CD45 
14 CD3 CD122 CD56 CD95 
 
2.3.3 Cell stimulation and culture  
For T-cell activation, a human antibody directed against the CD3 molecular 
complex was used in combination with a co-stimulatory human anti-CD28 antibody. 
2.3.3.1 Preparation of anti-CD3 coating plates 
One mg/mL stock solution of anti-human CD3 antibody was diluted with PBS to a 
10 µg/mL working solution. Fifty µL of the diluted anti-human CD3 antibody 
working solution was distributed into each well of 96-well round-bottom plates. For 
the control wells (non-stimulated group), 50 µL of sterile PBS was added instead of 
anti-human CD3 antibody. The plate was covered and incubated for 90 min at 37 ºC. 
Excess antibody was then removed and the plate was washed twice with cold PBS 
200 µL/well. 
2.3.3.2 Cell culture 
  Pre-treated cells from step 2.3.2 were distributed into each well of the anti-CD3 
coated 96-well plate (see 2.3.3.1) for culture (200 µL/well, containing 2 x 105 
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pre-treated cells, 1 x 106 cells/mL). Anti-human CD28 stock solution (1 mg/mL) was 
added to each well for a final concentration of 2.5 µg/mL. The plate was placed in a 
humidified 37 ºC, 5% CO2 incubator for 48 hours (for BrdU staining) or 72 hours (for 
CFSE and cell surface marker analysis). 
 
Table 2.2 Combinations of immunosuppressive drugs 
Final Concentration 
Group 
MPA (µM) CsA (ng/mL) Tac (ng/mL) 
1 0 0 0 
2 0 0 0 
3 1 0 0 
4 10 0 0 
5 0 25 0 
6 0 100 0 
7 0 0 2 
8 0 0 10 
9 1 25 0 
10 1 0 2 
11 10 25 0 
12 10 0 2 
 
2.3.4 CFSE labeling and cell proliferation study 
  Healthy PBMC were resuspended (1 x 107/mL in PBS) with fluorescent dye CFSE 
added to a final concentration of 5uM, and the suspension was then incubated at room 
temperature for 5 min. At the end of this incubation, the cells were immediately 
washed twice with 10 volumes of PBS containing 5% FBS. The stained PBMC were 
resuspended with RPMI medium (1 x 106 cells/mL), treated with immunosuppressive 
drugs and cultured as indicated in 2.3.2 and 2.3.3.  After 72 hours, cells were 
harvested, incubated with anti-CD4 (PerCP-Cy5.5) and anti-CD8 (APC) antibody for 
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30min in an ice bath. The cells were subsequently washed and resuspended with 
staining buffer. CFSE staining (FL1-height) was measured by flow cytometry using a 
FACSCalibur and CellQuest Pro software. Lymphocyte, CD4 and CD8 positive cells 
were gated and data was analyzed by WinMDI 2.8 and Weasel 2.1 software (F. Battye, 
The Walter and Eliza Hall Institute of Medical Research).  
 
2.3.5 BrdU staining and cell cycle study 
  After 48 hours of cultured (2.3.3.2), the PBMCs were labeled for 30 min at 37ºC 
with 10uM BrdU in cell culture medium. Then the cells were harvested, fixed, 
permeabilized and stained with anti-BrdU and 7-AAD following the instructions of 
the BrdU Flow Kits. G0/G1, S and G2/M fractions were quantified by WinMDI 2.8. 
Cells that were not BrdU-labeled were used as negative staining control.  
 
2.3.6 Cells surface antigen study 
PBMCs were treated with immunosuppressive drugs, stimulated and cultured 
according to 2.3.2 and 2.3.3.  After 72 hours culture, cells were resuspended in 
staining buffer and labeled with antibodies (Table 2.3) for 30 min on ice. Then the 
cells were washed with staining/wash buffer twice and fixed with 2% 
paraformaldehyde in PBS.  The expression of each surface marker was measured by 
FACSCalibur and CellQuest Pro software. Forward scatter signal was collected in 
liner mode; sideward scatter and the four fluorescence signals were analyzed on a 
logarithmic scale.  Electronic compensation was adjusted to eliminate spectral 
overlap between FITC/PE, PE/Cy-Chrom and Cy-Chrom/APC channels, respectively.  
Non-stimulated PBMC were used as negative controls. Cells stained with the 
respective isotype served as control. Forward and sideward scatter was used to 
identify the lymphocyte gate, and subsequent analysis was performed on this gated set 
of cells; 10,000 cells per sample were counted. 
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Table 2.3 Combinations of antibodies for in vitro study 
FITC PE CY APC 
CD25 CD69 CD4 CD8 
CD71 CD154 CD4 CD8 
 
 
 
2.3.7 Cytokine Study. 
Healthy PBMC were treated with immunosuppressive drugs, stimulated and 
cultured in anti-human CD3-coated 12-well plate for 24 hours as description in 2.3.2 
and 2.3.3. For preparation of the plate, 300 µL of anti-human CD3 (10 µg/mL) 
antibody were added to each well instead of 50 µL as described in 2.3.3.1.  Each well 
contained 2 mL medium (2 x 106 cells) and the final concentration of anti-human 
CD28 is 2.5 µg/mL.  The groups of high concentration of MPA (10 µM) were 
omitted in this study. After 24 hours culture, the supernatant of each well was 
harvested and incubated with human cytokine capture bead following the instruction 
manual of the “Human Th1/Th2 Cytokine CBA” kit. The samples and serially diluted 
cytokine standard dilutions were analyzed by FACSCalibur and CellQuest Pro 
software. The threshold to FSC was set at 650 and other settings following the 
instructions of the kit. The raw data were analyzed by BD CBA Software (BD 
Biosciences, USA) to obtain standard curves. The levels of cytokines in supernatants 
were calculated automatically. Using this method, the levels of 6 kinds of cytokine 
proteins including IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ can be quantitatively 
measured in a single sample. 
2.3.8 Cytokine mRNA expression by real-time RT PCR 
Healthy PBMC were treated with immunosuppressive drugs, stimulated and 
cultured for 4 hours as description in 2.3.7. After the time of culture, cells were 
harvested and the total RNA was isolated by TRIzol reagent (Invitrogen) according to 
manufactures protocol. Briefly, 5-10×106 pellet cells were lysed in 1 mL TRIzol 
reagent. The homogenized samples were incubated for 5 minutes at room temperature 
and 0.2 mL of chloroform was added.  The samples were then centrifuged at 11,500
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× g for 15 minutes at 4°C. The aqueous phase of sample was isolated and 0.5 mL of 
isopropyl alcohol was used to precipitate the RNA. The RNA precipitates were 
centrifuged, washed with 1 mL 75% ethanol and redissolved in DEPC-treated water. 
The concentration of RNA samples were assessed by spectrophotometer and the ratio 
between the absorbance values at 260 and 280 nm gives an estimate of RNA purity.  
Sequence-specific PCR primers and fluorochrome-labeled internal oligonucleotide 
probes for IL-2, IFN-γ and TNF-α were designed. In order to rule out amplification of 
contaminating DNA, the primer sequences were designed to span exon-intron 
junction and checked in Genebank. Forward and reverse primers were synthesized by 
Carl Roth GmbH; the FAM-TAMRA labeled TaqMan probes were synthesized by 
QIAGEN (Table 2.4).  
Table 2.4 Primers and TaqMan probes for real-time RT PCR 
Primer Name Sequence (5'-3') 
Length 
 (bp) 
Genebank  
Accession No
Tm 
(°C)
IL2-F ACT CAC CAG GAT GCT CAC AT 61.5
IL2-R AGA TCC CTT TAG TTC CAG AAC 59.4
IL2-TP TTT TAC ATG CCC AAG AAG GCC ACA GAA CT 
 
 193 
  
GI:28178860 
  71.5
IFNγ-F TCA GCT CTG CAT CGT TTT G 62.2
IFNγ-R TCT GTC ACT CTC CTC TTT CCA 61.5
IFNγ-TP TTG GCT GTT ACT GCC AGG ACC CAT ATG T 
 
 166 
  
GI:32679 
  71.6
TNFα-F CAG GCA GTC AGA TCA TCT TC 59.3
TNFα-R CTC TGA TGG CAC CAC CAG 61.1
TNFα-TP TAG CCC ATG TTG TAG CAA ACC CTC AAG CT 
 
 165 
  
GI:339737 
  71.6
Actinβ-F ACC GAG GCC CCC CTG 63.1
Actinβ-R GGT CTC AAA CAT GAT CTG GGT CA 63.4
Actinβ-TP ACC CCA AGG CCA ACC GCG A 
 
 62 
  
GI:5016088 
  72.5
F: forward primer; R: reverse primer; TP: TaqMan probe. 
Quantitative RT-PCR was carried out on a 7700 Sequece Detector Systems and 
Sequence Detection system (SDS) Software (Applied Biosystems, Foster City, CA, 
USA) using the ∆∆Ct method of calculating the relative expression (Simon et al., 
2003). Briefly, gene expression was determined from measurements of the increase in 
fluorescence, corresponding with exponential amplification and degradation of the 
bi-fluorescent probe during the PCR reaction. The cycle in which fluorescence 
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exceeds the manually set threshold level of detection is termed the ‘threshold cycle’ 
(Ct value). Greater amounts of initial specific template add to the reaction will result 
in threshold-exceeding fluorescence during earlier cycles (lower Ct value).  Thus, 
the Ct value is inversely proportional to the log of the input target specific mRNA 
(IL-2, IFN-γ and TNF-α, in this study). All Ct value measurements were obtained for 
each sample (target gene and β-actin endogenous control). The Ct value of the 
endogenous control gene was used to calculate normalized target gene expression, 
referred to as ‘delta Ct (∆Ct), in order to correct differences between samples; ∆Ct 
values for each target gene in individual samples were calculated as follows: 
∆Ct (target gene) = Ct (target gene) – Ct (β-actin mRNA) 
  Calculation of relative gene expression was then performed, which allowed for 
comparison of the gene expression in one sample relative to another. The sample on 
which the comparison is based is termed the ‘calibrator’ sample and the sample that is 
being compared is referred to as the ‘target’ sample. For this study, we presented 
calibrated gene expressions from samples stimulated by anti-CD3/anti-CD28 antibody 
and treated by immunosuppressants relative to non-stimulated sample. This 
calculation is accomplished by the use of two formulas. First, the normalized ∆Ct 
values for calibrator and target sample are substituted into the delta-delta CT (∆∆Ct) 
equation: 
  ∆∆Ct = target sample ∆Ct – Calibrator sample ∆Ct 
The relative expressions then calculated according to the formula: 
Relative expression = 2–∆∆Ct  
Calibrator expression is always considered one. The relative amounts of target 
IL-2, IFN-γ and TNF-α mRNA of other groups were obtained by comparing them to 
the calibrator. All PCR reactions were carried out in duplicate on each one-step RT 
PCR and the average ∆∆Ct was used to calculate relative expression. 
Using TaqMan One-Step RT-PCR Master Mix Reagents Kit, the RT and PCR 
amplification occur at one step without interruption. All reactions were performed 
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with 96-well microtitre plates and each reaction volume was 25 µL.  The One-Step 
RT PCR conditions were 30 min at 48 ºC for RT, 10 min at 95 ºC for 
DNA-polymerase activation, followed by 40 cycles of 15s at 95 ºC for denaturation 
and 1 min 30s at 60 ºC for annealing/extension with a final 25 ºC hold.  
Table 2.5 RT-PCR Reaction  
Rx component Volume per 
Rx (µL) 
Volume for 100 
Rx (µL) 
Final Value 
2 x Master Mix  12.5 1250 1 x 
40 x MultiScribe and 
Rnase Inhibitor Mix 
0.625 62.5 0.25U/µL 
0.4U/µL 
10 µM Forward Primer 1 100 400 nM 
10 µM Reverse Primer 1 100 400 nM 
5 µM TaqMan probe 0.5 50 100nM 
RNA sample 2  0.2ng to 20ng 
Water 7.375 737.5  
Total 25 2300  
 
2.4 Statistical Analysis 
  All data are expressed as mean ± SD. For statistical analysis, SPSS version 8.0 
(SPSS Corp., Birmingham, AL) was used.  Nonparametric test was used and a value 
of P<0.05 was considered to be significant. The one-way ANOVA with the 
Student-Newman-Keuls (SNK) post hoc test was used to estimate the levels of 
significance for the differences between more than two groups. 
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3. Results 
3.1 Monitoring of surface markers of PBMC in liver transplant patients 
  After 4 months of conversion to combined MMF/CNI reduction therapy (MMF 2 
g/day), the mean trough levels of Tac and CsA in the MMF/CNI reduction group were 
2.2 ± 0.5 ng/mL and 36 ± 9.1 ng/mL respectively.  For controls, the mean trough 
levels of CsA and Tac were 116 ± 19.4 ng/mL and 5.6 ± 1.3 ng/mL respectively.   
  In the MMF/CNI reduction group, the percentage of CD8+ T cells (CTL) was 
significantly lower than the control group (P<0.05; Table 3.1, Figure 3.1). The 
percentages of CD3+CD56+ T cells (NK T cells) (P<0.005; Table 3.1, Figure 3.2) and 
CD4+CD45RO+ T cells (memory T cells) (P<0.01; Table 3.1, Figure 3.3) also 
decreased significantly in the MMF/CNI reduction group. 
 
Table 3.1 Percentage of CD8+ T cells, CD3+CD56+ NK T cell and CD4+CD45RO+ 
T cells in the MMF/CNI reduction group and control group 
 
  MMF/CNI reduction group (%) Control Group (%) 
CD8+ T cells 20.34 ± 8.14 29.09 ± 9.66 
CD3+CD56+ NK T cells 5.71 ± 1.66 9.68 ± 3.08 
CD4+CD45RO+ T cells 57.99 ± 11.98 72.88 ± 8.3 
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Figure 3.1 Percentage of cels expressing CD3 (T cells), CD4 (Th) ,CD8 (CTL) in the 
MMF/CNI reduction group versus control group. Values are expressed as mean ± SD. 
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Figure 3.2 Percentage of CD3+CD56+ NK cells in the MMF/CNI reduction group versus 
control group. Values are expressed as mean ± SD. 
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Figure 3.3 Percentage of CD4+CD45RO+ T cells (memory T cells) in the MMF/CNI reduction 
group versus control group. Values are expressed as mean ± SD. 
 
  To assess the function of lymphocytes, the expression of activation markers (CD25, 
CD69, CD71 and CD154) was investigated (Table 3.2). The expression of CD71 on 
CD4 cells was significantly lower in the MMF/CNI reduction group (P<0.05; Figure 
3.4). In the MMF/CNI reduction group, there was a trend towards lower CD154 
expression on CD4 T cells (P=0.08; Figure 3.4)  
  We also found that the percentage of γδTCR+ T cells was significantly lower in the 
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MMF/CNI reduction group than in the control group (20.06% ± 8.64% vs 29.49% ± 
8.90%, P<0.05; Figure 3.5). 
 
Table 3.2 Expression of activation surface markers on CD4 T cells in the 
MMF/CNI reduction group and control group 
  MMF/CNI reduction group (%) Control Group (%) 
CD25 7.88 ± 10.39 6.59 ± 2.72 
CD69 12.10 ± 8.12 20.45 ± 11.34 
CD71 6.54 ± 2.93 11.36 ± 5.90 
CD154 6.73 ± 3.10 11.76 ± 7.80 
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Figure 3.4 Expression of CD71 and CD154 on CD4+ T cells in the MMF/CNI reduction 
group versus control group. Values are expressed as mean ± SD. 
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Figure 3.5 Percentage of γδTCR on T cells in the MMF/CNI reduction group versus control 
group. Values are expressed as mean ± SD. 
 
3.2 In vitro study of lymphocyte function  
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3.2.1 MPA and CNI inhibit T cell proliferation 
  To assess how MPA and CNI interfere with the expansion of activated lymphocytes, 
healthy human PBMC were activated with anti-CD3 antibody and anti-CD28 
antibody in the presence of MPA and CNI (Table 2.2). By labeling PBMC before cell 
division with fluorescent dye CFSE, cell division can be monitored by the decrease in 
dye content of the cells as the dye is divided between daughter cells. After 3 days in 
the presence of anti-CD3 antibody and anti-CD28 antibody, 65.74% of lymphocytes 
had undergone one to four divisions, and only 34.26% of the cells remained undivided. 
Addition of 1 µM MPA at the onset of the culture inhibited cell division completely. 
Neither CsA nor Tac alone blocked T cells going into daughter division. However, 
both of them reduced the number of cells in each division generation (P<0.001 vs 
stimulation group) and this effect was stronger in high dose CsA group (100 ng/mL) 
than that in lower concentration CsA group (25 ng/mL) (P<0.001). Combined MMF 
and CsA or Tac inhibited almost all of lymphocytes division (Table 3.3, Figure 3.6).  
MPA blocked proliferation of both CD4 and CD8 subpopulations (Figure 3.7) 
Table 3.3 Percentage of division 0 in the presence of immunosuppressive drugs 
Groups Percentage of cells of Division 0 
Non-stimulated PBMC 95.50±3.10 
Stimulated PBMC 34.26±6.73 
MPA 1 µM  99.58±0.56 * 
MPA 10 µM  97.68±1.92 * 
CsA 25 ng/mL  40.43±3.99 *  
CsA 100 ng/mL     48.89±2.91 *  § 
Tac 2 ng/mL     54.86±4.56 *  § 
Tac 10 ng/mL     54.56±3.00 *  § 
MPA 1 µM+ CsA 25 ng/mL  97.41±5.22 * 
MPA 1 µM+ Tac 2 ng/mL  99.74±0.19 * 
MPA 10 µM+ CsA 25 ng/mL  99.97±0.04 * 
MPA 10 µM+ Tac 2 ng/mL  99.98±0.02 * 
* vs stimulation group, P<0.001 
§ vs CsA 25ng/mL group, MPA alone and other combined MPA /CNI groups, P<0.001 
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Figure 3.6 Antiproliferative effects of MPA and CNI in primary T lymphocytes.  PBMC were labele
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3.2.2 MPA inhibits PBMC from G0/G1 transition to S phase
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Table 3.4 Percentage of PBMC in each phase of cell cycle 
Groups G0/G1 Phase S Phase G2+M Phase 
Non-stimulated 94.07±0.97 0.47±0.12 5.50±0.92 
Stimulated 60.30±0.66 * 31.50±0.62 8.20±0.26 
MPA 1 µM 74.77±0.75 12.73±0.25 12.57±0.91 
MPA 10 µM 83.17±2.40 5.63±0.64 11.13±1.80 
CsA 25 ng/mL 78.23±1.42 13.6±1.40 8.27±0.70 
CsA 100 ng/mL 78.63±2.38 12.17±2.50 9.17±1.00 
Tac 2 ng/mL 81.57±1.89 10.00±2.21 8.13±0.35 
Tac 10 ng/mL 83.1±1.40 8.87±0.25 8.07±1.10 
MPA 1 µM+ CsA 25 ng/mL 79.67±0.47 9.37±1.34 10.97±1.15 
MPA 1 µM+ Tac 2 ng/mL 87.07±0.85 ** 4.57±0.51 8.37±0.84 
MPA 10 µM+ CsA 25 ng/mL 85.83±1.91 § 3.80±0.90 10.40±1.85 
MPA 10 µM+ Tac 2 ng/mL 90.57±0.92 ** 2.70±0.60 6.73±0.47 
*  vs non-stimulated and immunosuppressant groups, P<0.001 
** vs MPA or CNI alone groups, P<0.001 
§  vs MPA 1 µM, CsA alone, Tac 2 ng/mL and MPA 1 µM + CsA 25 ng/mL groups, P<0.001. 
 
 
3.2.3 MPA and CNI inhibited blastogenesis and the expressions of activation 
markers 
  Progression from quiescent state (G0) into and through the G1 phase of the cell 
cycle is characterized by RNA synthesis, decondensation of the chromatin, cellular 
enlargement, and synthesis of new proteins.  Cellular enlargement as well as 
up-regulation of the activation marker CD69, the IL-2R α-chain CD25, CD154, and 
the transferrin receptor CD71, were analyzed by FACS (Figure.3.9). As expected, 
anti-CD3/anti-CD28 antibody stimulation induced an increase in the forward scatter 
of the cells and triggered CD69, CD25, CD154, and CD71 expression (Figure 3.9, 
Table 3.5, 3.6). At day 3, up-regulation of CD25 and CD71 expression were blocked 
by MPA. CNI also partially blocked the expression of CD25, CD69 and CD71. Both 
MPA and CNI alone strongly inhibited the up-regulation of CD154 expression. 
Combined MPA and low concentration of CNI inhibited the expression of CD25, 
CD71 and CD154 as well as the development of lymphoblasts characterized by an 
increase in size. In this study, we didn’t find that MPA or MPA plus CNI inhibited 
the expression of CD69 after three days of stimulation.  
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Figure 3.8.  Effect of MPA and CNI inhibition of PBMC from G0/G1 transition to S phase of the cell cycle. PBMC were activated by
anti-CD3/anti-CD28. After 48h of incubation, cell were incubated with BrdU for 30 min.  The fraction of cells engaged in G0/G1 and S
phases were evaluated. BrdU-labeled cells were stained with FITC conjugated anti-BrdU antibody and 7AAD. Percentages of cells in
G0/G1 (lower left quadrant), S (upper left and right quadrant) and G2/M (lower right quadrant) phases of the cell cycle are indicated in
each dot plot. Results are representative of one among three independent experiments and show similar results. 
Table 3.5 Expression of activation markers on CD4 T cells 
 CD25 CD69 CD71 CD154 
1. Non-stimulated 12.10±2.16† 12.76±3.98† 18.80±5.34† 6.13±2.09 
2. Stimulated 95.68±2.26* 55.38±20.98 94.20±1.97* 48.26±16.91*
3. MPA 1 µM 73.05±5.82 42.90±5.99 62.37±8.65 15.36±4.38 
4. MPA 10 µM 74.50±2.73 56.45±5.50 60.88±9.65 7.52±4.00 
5. CsA 25 ng/mL 91.01±1.70* 42.67±4.55 85.69±2.80* 32.90±12.66*§
6. CsA 100 ng/mL 83.22±4.33 35.37±5.45§ 73.42±5.43 17.93±5.16 
7. Tac 2 ng/mL 77.47±3.97 35.60±3.11§ 63.67±6.39 11.70±5.46 
8. Tac 10 ng/mL 78.42±4.24 32.37±6.23§ 63.98±5.09 14.98±5.69 
9.MPA 1 µM + CsA 25 ng/mL 76.70±5.75 47.47±1.35 66.80±10.27 5.17±1.16 
10. MPA 1 µM + Tac 2 ng/mL 64.40±5.08** 39.50±7.96 44.88±9.50** 3.85±1.03 
11. MPA 10 µM + CsA 25 ng/mL 69.95±2.84 63.30±2.84 57.15±6.65 8.32±3.38 
12. MPA 10 µM + Tac 2 ng/mL 62.40±5.79** 41.73±5.85 40.23±7.62** 3.57±1.37 
† vs groups 2-12, P<0.001 
* vs group1 and group3,4,6-12, P<0.001 
** vs group 3,4,6-9, P<0.001 
§ vs group 2, P<0.001 
 
 
Table 3.6 Expression of activation markers on CD8 T cells 
 CD25 CD69 CD71 CD154 
1. Non-stimulated 1.20±0.35† 5.08±2.34† 0.71±0.27† 0.04±0.05 
2. Stimulated 93.79±1.89* 46.32±25.46 93.32±2.18‡ 28.46±9.53* 
3. MPA 1 µM 68.22±3.27 34.30±6.63 54.10±8.63 2.90±3.04 
4. MPA 10 µM 66.55±3.96 47.10±6.18 51.30±10.18 0.89±0.97 
5. CsA 25 ng/mL 86.22±3.02* 33.05±4.96 79.16±8.82 15.42±5.49*§
6. CsA 100 ng/mL 77.70±4.27 32.80±3.90 74.00±3.74 6.75±4.89 
7. Tac 2 ng/mL 75.70±2.72 32.40±3.64 69.60±4.48 5.62±3.58 
8. Tac 10 ng/mL 72.40±2.21 30.00±5.22 65.80±2.16 6.42±3.28 
9. MPA 1 µM + CsA 25 ng/mL 67.50±3.36 41.80±2.52 61.05±4.54 0.58±0.33 
10. MPA 1u M + Tac 2 ng/mL 57.00±5.47** 34.40±7.86 45.97±5.93 0.53±0.26 
11. MPA 10 µM + CsA 25 ng/mL 63.30±4.20 56.70±5.30 52.95±4.72 1.35±1.16 
12. MPA 10 µM + Tac 2 ng/mL 49.90±4.07** 35.70±4.39 37.65±5.27 0.43±0.25 
† vs groups 2-12, P<0.001 
* vs group1 and group3,4,6-9,11, P<0.001 
** vs group 3,4,6-9, P<0.001 
§ vs group 2, P<0.001 
‡ vs group 1,3-12, P<0.001 
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Figure 3.9 Effects of MPA and CNI on blastogenesis and the expression of activaton markers.  
PBMC were stimulated with anti-CD3/anti-CD28 antibody alone or in the presence of MPA/CNI. 
After 72 hours, the expressions of activation markers (CD25, CD69, CD71 and CD154) were 
analyzed by FACS. Results are representative of one among three independent experiments and 
show similar results. 
 38
  
CD25            CD69            CD71            CD154 
Anti-CD3/anti-
CD28  
Tac 2 ng/mL 
 
Anti-CD3/anti- 
CD28  
Tac 10 ng/mL 
 
Anti-CD3/anti-
CD28  
MPA 1 µM 
CsA 25 ng/mL 
 
Anti-CD3/anti-
CD28  
MPA 1 µM 
Tac 2 ng/mL 
 
Anti-CD3/anti-
CD28  
MPA 10 µM 
CsA 25 ng/mL 
 
Anti-CD3/anti-
CD28  
MPA 10 µM 
Tac 2 ng/mL 
 
Figure 3.9 (Continue) Effects of MPA and CNI on blastogenesis and the expression of 
activaton markers..  PBMC were stimulated with anti-CD3/anti-CD28 antibody alone or in the 
presence of MPA/CNI. After 72 hours, the expressions of activation markers (CD25, CD69, CD71 
and CD154) were analyzed by FACS. Results are representative of one among three independent 
experiments and show similar results. 
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3.2.4 Effects of MPA and CNI on the cytokine expression of lymphocytes 
  To assess the effects of MPA and CNI on the cytokine expression of lymphocytes, 
human PBMC were activated with anti-CD3/anti-CD28 antibody in the presence or 
absence of MPA and/or CNI.  After 24 hours of stimulation, the supernatant of cell 
cultures were harvested and the cytokine levels were measured using the ‘Human 
Th1/Th2 Cytokine CBA kit’ for IL-2, IL-4, IL-5, IL-10, TNF-α and IFN-γ. The data 
was collected by flow cytometry and analyzed by BD CBA software. The standard 
curves of each cytokine were performed (Figure 3.10). The final levels of Th1 and 
Th2 cytokine of Th1 cells (Table 3.7, figure 3.11) and Th2 cells (Table 3.8, figure 3.12) 
were calculated.  
  Non-stimulated PBMC secreted cytokine proteins at very low levels.  
Anti-CD3/anti-CD28 antibody stimulation induced all six cytokines significantly. 
Addition of MPA did not change the up-regulated secretion of cytokines at all. 
However, low dose of CNI and Tac strongly inhibited IL-2, IL-4, IL-10 and IFN-γ 
secretion. Combined MPA and low dose of CNI did not show more effects than CNI 
alone.  
 
 
Table 3.7 Cytokine levels of Th1 cells 
Group IL-2 (pg/mL) IFN-γ (pg/mL) 
1.Non-stimulated 0.00±0.00 * 0.00±0.00 
2. Stimulated 3621.93±487.70 ** 377.53±42.08.00 § 
3. MPA 1 µM 4490.77±882.02 ** 363.40±28.64 § 
4. CsA 25 ng/mL 972.90±133.48 0.00±0.00 
5. CsA 100 ng/mL 836.27±207.29 0.00±0.00 
6. Tac 2 ng/mL 413.03±84.13 0.00±0.00 
7. Tac 10 ng/mL 408.10±88.31 0.00±0.00 
8. MPA 1 µM + CsA 25 ng/mL 1111.73±35.80 27.28±19.43 
9. MPA 1 µM + Tac 2 ng/mL 571.97±168.45 19.79±23.81 
* vs groups 2-9, P<0.001 
** vs groups 4-9, P<0.001 
§ vs groups 1, 4-9, P<0.001 
 40
     
     
     
 
Figure 3.10 Standard curves of IFN-γ, IL-2, IL-4, IL-5, IL-10 and TNF-α 
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Table 3.8 Cytokine levels of Th2 cells 
 IL-4 (pg/mL) IL-5 (pg/mL) IL-10 (pg/mL) TNF-α (ng/mL)
1. Non-stimulated 0.00±0.00 0.00±0.00 0.93±1.62 0.024±0.003 * 
2. Stimulated 169.27±17.16 ** 271.87±32.76 103.90±16.49 ** 11.27±1.01 
3. MPA 1 µM 216.60±60.31 ** 353.47±115.28 ** 110.30±44.60 ** 34.06±8.52 
4. CsA 25 ng/mL 51.27±7.10 260.67±34.18 30.00±3.87 24.96±6.18 
5. CsA 100 ng/mL 42.47±9.07 222.80±48.30 32.80±7.86 26.15±2.36 
6. Tac 2 ng/mL 28.40±1.15 159.37±18.20 45.40±6.36 23.05±11.43 
7. Tac 10 ng/mL 27.23±8.21 154.13±28.81 45.80±10.57 16.82±7.29 
8. MPA 1 µM + CsA 25 ng/mL 52.03±3.27 229.57±20.75 26.90±1.68 22.05±4.50 
9. MPA 1 µM + Tac 2 ng/mL 32.73±7.95 169.93±32.26 52.90±12.52 19.19±10.01 
* vs groups 2-9, P<0.001 
** vs groups 4-9, P<0.001 
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Figure 3.11 Th1 cytokine expression after 24h of stimulation. A: IL-2 levels. B: IFN-γ levels. 
Values are expressed as mean ± SD from three independent experiments. 
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Figure 3.12 Th2 cytokine expression after 24h stimulation. A: IL-4 levels, B: IL-5 levels, C: 
IL-10, D: TNF-α. Values are expressed as mean ± SD from three independent experiments. 
 
3.2.5 CNI but not MPA inhibited NFAT-regulated cytokine mRNA expression of 
lymphocytes 
  We next analyzed whether MPA or CNI affected NFAT-regulated cytokine (IL-2 
and IFN-γ) mRNA or TNF-α mRNA expression (Table 3.9, Figure 3.13). Cytokine 
mRNA was quantified using a competitive quantitative real-time RT PCR method. 
The non-stimulated group served as calibrator. After anti-CD3/CD28 antibody 
stimulation, the expression of IL-2 mRNA was increased to 1500-fold as compared to 
the non-stimulated group and IFN-γ was increased 760-fold. Addition of MPA did not 
affect the up-regulation of mRNA expression of the two cytokines. Low dose of CNI 
or combined MMF/CNI inhibited IL-2 and IFN-γ mRNA expression significantly. 
However, we didn’t find inhibited expression of TNF-α mRNA in this study. This 
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result is in line with the TNF-α level presented in Table 3.8. 
 
Table 3.9 Relative expression of IL-2, IFN-γ and TNF-α mRNA 
Group IFN-γ IL-2 TNF-α 
1. Non-stimulated 1 1 1 
2. Stimulated 761 * 1573 * 37 
3. MPA 1 µM 581 * 2012 * 38 
4. CsA 25 ng/mL 32 150 30 
5. CsA 100 ng/mL 16 119 39 
6. Tac 2 ng/mL 10 102 81 
7. Tac 10 ng/mL 7 178 86 
8. MPA 1 µM + CsA 25 ng/mL 59 582 98 
9. MPA 1 µM + Tac 2 ng/mL 10 88 49 
* vs groups 1 and 4-9, P<0.001 
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Figure 3.13 Effects of MPA and CNI on the expression of IL-2, IFN-γ and TNF-α mRNA. 
PBMC were activated with anti-CD3/anti-CD28 antibody in the presence or absence of MPA 
and/or CNI. The expression of IL-2 (A), IFN-γ (B) and TNF-α (C) mRNA were analyzed by 
real-time RT PCR. Values are expressed as mean ± SD from three independent experiments. 
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 4. Discussion 
The major effect of immunosuppressive treatment is to prevent the 
activation-induced proliferation of T cells essential for the immune response 
(Nakamura et al., 2001). Immunosuppressive therapy in clinical transplantation has 
developed with the initial use of the triple drug regimen of CsA, prednisolone and 
AZA. Later Tac and MMF have been introduced immunosuppressants, which 
effectively prevent allograft rejection with a low incidence of side effects in the 
impaired natural host defenses. Immunosuppressive drugs are regularly used in 
distinct combinations, intended to maximize immunosuppression while reducing the 
adverse effects of each individual drug (Barten et al., 2003).  
4.1 Potencies and efficacies of various single immunosuppressive drugs after 
anti-CD3/anti-CD28-activated lymphocyte function. 
4.1.1 Inhibition of lymphocyte function by CNI 
CsA and Tac differ in their structure, but show similar actions.  CsA and Tac 
inhibit IL-2-dependent growth and differentiation of activated lymphocytes. CsA 
causes a different pattern of cell division blockage than MPA. The cells continue to 
divide, but in lower numbers in each division generation as CsA dosage is increased; 
MPA, on the other hand, is associated with blockage of progression to multiple 
division generations. This could be consistent with the major difference in action on 
activation per se (Nakamura et al., 2001).  
In this study, neither therapeutic level of CNI (100 ng/mL CsA, 10 ng/mL Tac) nor 
sub-therapeutic level of CNI (25 ng/mL CsA, 2 ng/mL Tac) completely blocked 
lymphocyte cell division. However, they reduced the number in each division 
generation and kept more cells in division 0 (Figure 3.6). For CsA, this effect was 
dose dependent. Tac blocked 54.9% cells into division at 2 ng/mL concentration and 
this effect was not enhanced when increasing its concentration to 10 ng/mL. 
Both CsA and Tac blocked cells at G0/G1 phase after anti-CD3/CD28-stimulation. 
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One of the key events during G1 phase is the synthesis of IL-2 by activated T 
lymphocytes. IL-2 production is required for progression of T cells through G1 into 
the S phase of the cell cycle (Quemeneur et al., 2002).  We hypothesized that 
sub-therapeutic levels of CNI also inhibited IL-2 effectively and following 
experiments of NFAT-regulated gene expression confirmed it. 
Calcineurin dephosphorylates NFAT family members, allowing them to translocate 
into the nucleus and activate gene expression through the cis-element named NFAT 
(Flanagan et al., 1991; Northrop et al., 1994; Shaw et al., 1995; Loh et al., 1996; 
Timmerman et al., 1996). Activated calcineurin also translocates into the nucleus 
together with NFAT family members, where it may maintain the sustained activation 
of NFAT proteins (Shibasaki et al., 1996). Among NFAT family members, NFAT1, 
NFAT2, and NFAT4 are involved in the transcriptional activation of genes encoding 
cytokines including IL-2, IL-4, CD154 (CD40L) (Ho et al., 1996; Rao et al., 1997) 
and IFN-γ (Giese et al., 2004). By preventing their calcineurin-mediated 
dephosphorylation, CNI inhibit the nuclear translocation of these NFAT family 
members and subsequent gene expression in activated T cells. Undoubtedly, inhibition 
of the calcineurin-NFAT pathway is one of the mechanisms of CsA/Tac-mediated 
immunosuppression (Matsuda and Koyasu, 2000). Sakuma et al (Sakuma et al., 2000) 
noted that anti-CD3/anti-CD28-costimulated IL-2 and IFN-γ mRNA expression in 
PBMC is significantly inhibited by the addition of low concentrations of Tac or CsA. 
Hartel et al (Hartel et al., 2004) also reported that the expression of IL-2 mRNA and 
TNF-α was inhibited by Tac. However, several studies demonstrated that IL-2 
expression in purified T cells or peripheral blood lymphocytes, induced by the 
co-stimulatory B7/CD28 pathway, is resistant to inhibition by Tac in vitro, even with 
drug concentrations of 100 µg/L (Lin et al., 1991; Anderson et al., 1999; Bierer et al., 
1991).  
In our study, either therapeutic or sub-therapeutic doses of CsA/Tac inhibited IL-2, 
IL-4, IL-10, IFN-γ expression and IL-2, IFN-γ mRNA expression significantly (Table 
3.7, 3.8 and 3.9; Figure 3.11, 3.12 and 3.13). Increased concentrations of CNI did not 
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show more inhibitary effect on cytokine expression. Previous reports demonstrated 
that the effects of Tac were evident at concentrations 20-100 times lower than that 
required for CsA (Andersson et al., 1992). We also noticed the trend that the inhibition 
effect of Tac on IL-2, IL-4 expression (Figure 3.11 A, figure 3.12A) was stronger than 
that of CsA although the data were not statistically significant. In contrast with 
Sakuma (Sakuma et al., 2000) and Hartel (Hartel et al., 2004), we didn’t find that CsA 
or Tac revealed inhibited expression of TNF-α and TNF-α mRNA in this study. Th1 
cells preferentially produce IL-2 and IFN-γ, which promote cellular immune response 
against intracellular pathogens, whereas Th2 cells produce IL-4, IL-5, IL-6 and IL-10, 
which promote humoral immunity by aiding in B cell activation and differentiation, 
leading in particular to production of IgG1 and IgE (Viola and Rao, 1999).  Our data 
and other studies showed that CNI do not only inhibit T cell function but also 
influence the synthesis of B cells by direct inhibition or via the inhibition of Th2 
associated cytokines (Stark et al., 2002), even though at sub-therapeutic level. 
To assess T cell function, the expression of activation surface markers were studied. 
CD25 is an IL-2 receptor and presents on a subset of peripheral blood lymphocytes.  
The density of CD25 increases on PHA, Con A and CD3-activated T lymphocytes. 
CD69 antigen is present on activated T, B, and NK lymphocytes. CD71 is a human 
transferrin receptor. The transferrin receptor is essential for iron transport into 
proliferating cells. CD71 antigen is expressed on all cells upon activation. CD154 
(CD40 ligand, CD40L) antigen is a member of the tumor necrosis factor (TNF) 
receptor family and is transiently expressed on activated CD4 T lymphocytes.  The 
expression of CD154 by activated T-helper cells triggers B-cell cyclin through 
binding to CD40. This co-receptor interaction is required for B-lymphocyte 
maturation, response to T-dependent ligands, and immunoglobulin class switching.  
T-lymphocyte proliferation and generation of CTL is associated with the presence of 
CD154 (Fuleihan et al., 1994; van Kooten et al., 1994; Banchereau et al., 1994; 
Nishioka and Lipsky, 1994). CD154-CD40 interaction is an essential step in the 
initiation of allograft rejection (Van Rijen et al., 2002).  
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We observed that both CsA and Tac inhibited expression of all activation surface 
markers in vitro, especially CD154. Higher concentrations of CsA further inhibiteded 
T-cell surface antigen expression such as CD25, CD71 and CD154. This finding is in 
accordance with other studies (Van Rijen et al., 2003; Van Rijen et al., 2002; Barten et 
al., 2001b). No difference was observed at both concentrations of Tac indicating that 
sub-therapeutic concentration of Tac also has enough inhibititary effect on expression 
of lymphocyte surface antigens.  
Summary: CNI did not block lymphocyte cell division. However, they reduced the 
T-cell number in each division generation and kept more cells in division 0. 
Sub-therapeutic level of CNI effectively inhibited NFAT-regulated genes and their 
proteins expression such as IL-2, IL-4, IL-10 and IFN-γ. Both CsA and Tac inhibited 
the expression of activation surface markers. However, the inhibition effect of CsA 
was dose dependent under our experimental conditions. 
4.1.2 Inhibition of lymphocyte function by MPA 
MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme of the 
de novo purine pathway.  Both T and B cells are preferentially inhibited by the 
antimetabolic effect of the drug. MPA arrests the cell cycle at G1. Purines control both 
G1 to S phase transition and progression through the S phase. Purine nucleotides play 
critical roles in DNA and RNA synthesis as well as in membrane lipid biosynthesis 
and protein glycosylation. They are necessary for the development and survival of 
mature T lymphocytes. Activation of T lymphocytes is associated with an increase of 
purine pools (Quemeneur et al., 2003). Animal models and in vitro studies show that 
B cells are also target cells of MPA. Not only was the proliferation of lymphocytes 
reduced, the immunoglobulin and cytokine production were also decreased (Jonsson 
and Carlsten, 2003; Stark et al., 2002). Previous study showed that DNA synthesis in 
PHA-stimulated PBMC was suppressed completely by 1 µM MPA (Allison and 
Eugui, 2000). In clinical studies, the trough levels of MPA were 6-12 µM (Pou, 2001). 
In our in vitro experiments, we selected 1 µM and 10 µM MPA as study 
concentration. 
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In our study, the proliferation of lymphocytes was investigated using CFSE staining. 
The proliferation of lymphocytes induced by anti-CD3/anti-CD28 antibodys was 
completely inhibited in the presence of 1 µM MPA (Figure 3.6). MPA affects both 
CD4 and CD8 in parallel (Figure 3.7). No difference was observed between 1 µM 
MPA group and 10 µM MPA group. Unlike CNI, which allows multiple cell 
generations but suppression of the numbers of cells in each generation, MPA blocked 
proliferation into subsequent generations completely. These findings corroborate 
earlier in vitro studies (Ogawa et al., 2001; Jonsson and Carlsten, 2001; Nakamura et 
al., 2001).  
We found that in the presence of MPA, most of the cells did not incorporate BrdU 
and accumulated in the G0/G1 phase (Fig.3.3). The effect of 10 µM MPA group was 
stronger than that of 1 µM MPA group. Quemeneur et al (Quemeneur et al., 2003) 
demonstrated that inhibitors of de novo purine synthesis (MPA) prevent cell cycle 
progression and down regulated survival of activated T lymphocytes. Depletion of 
guanine nucleotide pools after inhibition of IMPDH by MPA potently inhibits cell 
cycle progression by arresting activated T cells in the G1 phase of the cell cycles.  
This effect was associated with inhibition of cyclin D3/CDK6 induction and 
down-regulation of the CDK inhibitor p27Kip1 following activation of PBMC 
(Laliberte et al., 1998; Quemeneur et al., 2002). Addition of purine synthesis 
inhibitors after activation did not allow further cell divisions in the presence of IL-2, 
suggesting that clonal expansion of T lymphocytes does not only require an initial 
purine pool expansion but rather a recurrent de novo synthesis of these pools for each 
division to proceed (Quemeneur et al., 2003). De novo purine synthesis does not only 
control the cell cycle, but also regulated survival of activated T lymphocytes.  
Inhibitors of de novo purine synthesis, like MPA, would prevent clonal expansion if 
given before and during antigenic stimulation or, alternatively, trigger apoptosis of 
cycling T cells (Quemeneur et al., 2003). 
There was not only suprpression of new DNA synthesis by MPA, but also 
suppression of the expression of several cell surface T cell activation markers (Barten 
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et al., 2001c; Jain et al., 2001; Van Rijen et al., 2003; Barten et al., 2001a). In our 
investigation, up-regulation of CD25, CD71 and CD154 induced by 
anti-CD3/anti-CD28 antibodies were inhibited by MPA (Table 3.5 and 3.6).  
Previous studies of MPA’s biochemical effects may explain the mechanisms of 
action by which MMF suppressed expression of specific T-cell surface activation 
antigens. MPA, which is a specific inhibitor of IMPDH, provides depletion of guanine 
nucleotides in lymphocytes. This may limit the synthesis of mRNA for these 
molecules. Because guanine nucleotides are necessary for glycosylation of 
lymphocyte proteins (Allison and Eugui, 2000; Gummert et al., 1999a) and because 
these surface antigen molecules are glycoproteins, MPA may alter their glycosylation 
pattern, resulting in a decrease of expression (Van Rijen et al., 2003).  Proliferating 
lymphocytes depend on both the purine and the pyrimidine pathways to supply 
ribonucleotides necessary for DNA, RNA and protein synthesis as well as for 
ribonucleotide intermediates, which are required for proper lipid and protein 
glycosylation and membrane synthesis (Fairbanks et al., 1995; Ruckemann et al., 
1998). In addition, studies in human cell lines showed that MPA suppresses the 
synthesis of RNA-primed DNA intermediates (Catapano et al., 1995).  In other 
studies, MPA has been shown to suppress guanine nucleotide protein (G-protein) 
levels (Mustelin, 1987), which are required for activation of some T-cell surface 
antigens (Lub et al., 1995). MPA also blocks the glycosylation of adhesion molecules 
(Allison and Eugui, 1996; Laurent et al., 1996); necessary for proper folding and 
regulation of other T-cell surface antigens (Hayes et al., 1995; Springer, 1990). 
However, addition of MPA did not modify up-regulation of the early G1 markers 
CD69 after 72 hours stimulation.  Previous studies showed that MPA did not 
interfere with initial activation events following TCR engagement such as blast 
transformation or CD69 expression (Quemeneur et al., 2002). Inhibition of 
lymphocyte antigen expression by MPA has been reported to highly correlating with 
MMF dose (Gummert et al., 1999a; Barten et al., 2002c). We also found that 
inhibition of CD154 expression induced by MPA is dose dependent (Table 3.5 and 
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3.6). 
As we expected, MPA did not inhibit expression of NFAT-regulated genes and 
their proteins at all. Unlike CsA and Tac, which inhibit early stages of lymphocyte 
activation, including the production of IL-2 (Thomson et al., 1993), MPA 
concentrations up to 10uM had not detectable effect on production of IL-2, IL-4, IL-5, 
IFN-γ and GM-CSF (Allison and Eugui, 2000). These findings emphasize the major 
differences between effects of CNI and MPA on lymphocytes. Recently, Weimer et al 
(Weimer et al., 2003) showed that MMF therapy suppressed LPA stimulated IL-10 
and TNF-α secretion in long-term renal transplant patients. IL-10 may have 
deleterious effects with respect to both acute and chronic rejection. IL-10 acts as a 
potent B-cell growth and differentiation factor and may augment humoral immune 
responses against the graft (Rousset et al., 1992; te Velde et al., 1992; Nonoyama et 
al., 1993; Llorente et al., 1995). MMF treatment may be expected to have beneficial 
effects not only on acute but also on chronic rejection as a result of suppression of 
IL-10 secretion. However, the exact phenotype and mechanisms of action of regulator 
T cells remain controversial (Womer et al., 2001). The Th1 and Th2 paradigm which 
holds that rejection is dependent on the expression of Th1 cytokines (IL-2, IFN-γ) and 
that tolerance is dependent on Th2 cytokines (IL-4, IL-5, IL-10 and IL-13) has been 
recently challenged. The existence of specific cytokine gene knock out mice indicates 
that Th1 cytokines may function not only to initiate cell-mediated immune responses 
but also to regulate T-cell responses (Womer et al., 2001).  
Summary: In this study, we demonstrated the inhibition effect of MPA on 
lymphocyte proliferation and on the expression of cell surface antigens. The 
immunosuppressive effect of MPA in clinical transplantation therefore may be related 
not only to inhibition of lymphocyte proliferation but also to the inhibition of cell 
surface antigen expression, which may be an important additional factor in limiting 
the alloresponse. MPA has no effect on expression of NFAT-regulated genes and their 
proteins. 
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4.2 Inhibition of lymphocyte function by immunosuppressant combination 
4.2.1 Synergistic effects of MPA with CsA and Tac in vitro 
Our in vitro studies revealed a greater overall inhibition of lymphocyte function for 
the combination MPA plus CsA or Tac. In vitro, addition of MPA to low 
concentrations of CsA (25ng/mL) or Tac (2ng/mL) led to a synergistic effect on 
inhibition of lymphocyte function. Analysis of CFSE staining showed complete 
inhibition of lymphocyte division when MPA combined with CsA or Tac (Table 3.3, 
figure 3.6). This effect was equal to MPA treatment alone. In combination with MPA, 
CsA or Tac acted synergistically at low concentrations to inhibit lymphocyte 
proliferation. More cells were blocked in G0/G1 phase than MPA or CNI 
monotherapy groups. Increasing concentrations of MPA enhanced inhibitory effect 
and 86-91% lymphocytes were blocked in G0/G1 phase (Table 3.4, Figure 3.8). This 
seems to be related to the capacity of PBMC to divide in response to residual IL-2 
produced in the presence of these levels of CNI, whereas the cell cycle blocking effect 
of MPA under these in vitro conditions is more complete (Ogawa et al., 2001). 
An increased maximal inhibition of T-cell surface antigens expression was noticed 
after combination drug therapy compared with MPA or CNI monotherapy. MPA 
showed an effective dose dependent inhibition of the expression of T-cell surface 
antigens (Table 3.5 and 3.6, Figure 3.9). MPA plus CNI, especially with Tac, almost 
completely inhibited expression of CD154 on activated T cells. 
Our data indicated that Tac and CsA specifically suppress inflammatory cytokine 
production triggered by T cell activation. However, addition of MPA did not show 
additive inhibitory effect on the expression of NFAT regulated cytokine as well as on 
the expressions of their mRNA.  
Barten et al (Barten et al., 2003) recently showed that the total inhibitory effect on 
both lymphocyte proliferation and activation was enhanced when MPA was combined 
with either CsA or Tac, compared to CsA, Tac mono-treatment. For the combination 
of Tac plus MPA, the extent of inhibition of lymphocyte function was greater 
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compared to the effect of the other drug combinations. In combination with CsA or 
Tac, MPA acted synergistically at low concentrations to inhibit lymphocyte 
proliferation. Increasing concentrations of MPA antagonized the CsA or Tac effect on 
lymphocyte proliferation. MPA concentrations potentiated synergistically the effect of 
Tac inhibitiving the expression of T cell surface antigens. In contrast, in combination 
with CsA the effect of MPA on T cell surface antigens was antagonistic regardless of 
the concentrations used. However, contrary to Barten’s results, we found that either 
low concentration of CsA or Tac was synergistic in combination with MPA in the 
inhibition of lymphocyte proliferation and expression of activation surface antigens. 
We assume that different drug combinations and distinct stimulation of lymphocyte 
are the main cause of differences between two experiments. 
4.2.2 Monitoring of surface markers of PBMC in liver transplant recipients 
Because the clinical relevance of combination therapy is certainly more important, 
we compared the CNI monotherapy with combination therapy of MPA with low dose 
of CNI (MMF/CNI reduction group). Interestingly, we found that the percentage of 
CD8 cells (CTL), CD56+CD3+NK T cells and memory T cells (CD4+CD45RO+) 
significantly decreased in MMF/CNI reduction group. The expression of CD71 on 
CD4 cells was significantly reduced in MMF/CNI reduction group. We also found a 
trend of decreased CD154 expression on CD4 cells. This result is in accordance with 
previous studies which also demonstrated that MPA in a dose-related fashion inhibits 
the generation of CTLs and the rejection of allogeneic cells (Allison and Eugui, 
2000). 
Generation of antigen-specific CTL is a major immunological effector mechanism 
in allograft rejection.  Today, it seems clear that CD8+ CTL play an important role in 
allograft rejection (Rocha et al., 2003). CD8+ CTL are primed and activated by 
recognition of donor MHC class I antigens. These antigens also serve as targets for 
the mature cytolytic effector. In the prevailing view, recipient CD8+ T cells are 
primed by direct presentation of donor antigens by ‘passenger’ APCs from the graft 
(Arakelov and Lakkis, 2000). Although donor APCs are the major pathways for CTL 
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induction, Kreisel et al (Kreisel et al., 2002) reported a novel mechanism of direct 
antigen presentation by activated donor vascular endothelial cells. This pathway can 
induce responder CD8+ T cells with an effector phenotype that is sufficient to cause 
acute rejection. Although the role of class I MHC antigens is unequivocal, the 
requirement for co-stimulatory molecules in the allogeneic priming of CTL is 
controversial. After cardiac transplantation, blockade of CD40–CD154 (CD40L) 
interactions has been variously reported to impair (Zhai et al., 2003) or to have no 
effect (Jones et al., 2000) on activation of allospecific CD8+ T cells.  
CD40 and its ligand CD154 represent conventional members of a second family of 
co-stimulatory molecules that belong to the TNF receptor and TNF superfamilies, 
respectively (Larsen and Pearson, 1997; Yamada and Sayegh, 2002). CD40 is 
constitutively expressed on APCs, such as B cells, macrophages and dendritic cells, 
and can also be induced on endothelia cells and fibroblasts (Larsen and Pearson, 
1997). CD154 is expressed after activation on CD4+ T cells, as well as on some CD8+ 
T cells, NK cells, and eosinophils (Rothstein and Sayegh, 2003). While there is 
limited evidence to suggest that CD154 directly provides signals to the T cell, CD40 
plays a major role in the activation and maturation of B cells and dendritic cells (Blair 
et al., 2000; van Essen et al., 1995). Thus, the CD40-CD154 interaction initially 
provides costimulatory signals to APCs rather than T cells. However, because such 
costimulation significantly augments the ability of APCs to present antigen, it strongly 
enhances T-cell activation (Rothstein and Sayegh, 2003). Thus, inhibition of 
expression of CD154 by MPA may have benefit for organ transplant recipients by 
interfering with the “second signal” of T cell activation. 
In MMF/CNI reduction group, the percentage of γδTCR+ T cells was significantly 
reduced. γδTCR+ T cells are relatively frequent in mucosal epithelia and have a 
specific repertoire of T-cell receptors biased towards certain bacterial/viral antigens. 
Current opinion is that these cells may have an important role in protecting the 
mucosal surfaces of the body. We hypothesize that over suppression of γδTCR+ T 
cells by immunosuppressants may make patients more susceptible to some 
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opportunistic infections. 
Summary: All our in vivo and in vitro data indicated that combination of MPA and 
sub-therapeutic levels of CNI increased the overall inhibition of lymphocyte function 
compared with CNI monotherapy. The synergistic effect of MPA with CNI does not 
only inhibit directly lymphocyte proliferation and activation marker expression, but 
blocks cytokine production as well. This effect of MPA is dose-dependent (Barten et 
al., 2002a).  
4.3 Further study 
Current therapeutic challenges associated with immunosuppressive drugs are 
directed toward minimizing toxicity through the use of effective combination therapy 
with new drugs such as MMF. On account of the narrow therapeutic ranges of CsA 
and Tac, the wide intra- and interindividual variations in their pharmacokinetics, as 
well as the potential for significant drug-drug interations, monitoring of blood levels 
and monitoring of the immunosuppressive drug effects over time are recommended to 
optimize therapy (Dambrin et al., 2000). Several studies revealed that trough MPA 
levels differ significantly according to the type of CNI (Cantin et al., 2002; Pou et al., 
2001). MMF also induces alterations of CsA metabolism (Pape et al., 2003). 
Infectious complications with the use of MMF have been questioned due to the 
perceived implication of increased immunosuppression (Smallwood et al., 2002). 
Therefore, monitoring of individual drug levels does not, however, provide enough 
information on the combined immunosuppressive effects of the different 
immunosuppressive drug protocols.   
Barten et al (Barten et al., 2002b) found that dose-dependent inhibition of 
lymphocyte function was higher for the combination of Tac and MMF than after a 
single drug treatment in vivo.  High correlations were found between the 
pharmacodynamic (PD) parameters AUC0-24 and Imax of lymphocyte function and 
drugs, thus suggesting a “diagnostic range” that may be a useful means to monitor 
drug combination therapy. 
MPA levels were related to efficacy and major adverse events in liver graft 
 56
recipients. Plasma MPA concentrations within patient groups were not closely 
correlated with the dose of mycophenolate mofetil but were dependent upon the 
indication for prescribing MMF, age and serum albumin and creatinine concentrations 
(Tredger et al., 2004).  Tredger et al (Tredger et al., 2004) reported that a therapeutic 
range of predose MPA plasma levels of 1 to 3.5 mg/L (by immunoassay) is applicable 
in liver allograft recipients. The potential for MPA toxicity at higher predose plasma 
levels is in agreement with the findings in renal transplant recipients of Mourad and 
colleagues (Mourad et al., 2001) who identified at 3 mg/L threshold using ROC curve 
analysis. MMF with the benefit of MPA monitoring, only 6.3% were considered to 
need 1.5 g twice a day clinically, and 44.7% were prescribed less than 1 g twice a day 
(Tredger et al., 2004). The drug levels were also influenced by the type of 
immunosuppressive comedication (Shaw et al., 2002). In a study of 61 children, MPA 
clearance was greatest during CsA comedication, least during Tac comedication and 
intermediate when MMF was given without either CNI agent. The underlying 
mechanism is suggested to be an inhibition of the excretion and enterohepatic 
recirculation of MPA glucuronide by CsA compared with inhibition of mycophenolate 
glucoronidation by Tac (Brown et al., 2002; Zucker et al., 1999). In a study of 33 
renal transplant patients whose immunosuppression was based on triple therapy 
regimen (MMF, CsA and steroids), 21% patients required one or more dose 
adjustments (Shaw et al., 1998). MPA PD exhibits large inter- and intrapatient 
variability and may be altered in specific patient populations due to changes in protein 
binding, concomitant disease states, or interactions with concurrent 
immunosuppressants. Therefore, clinical PD monitoring can provide more 
information regarding efficacy of MMF than clinical judgment alone (Cox and Ensom, 
2003). Lymphocyte function may be used to measure PD of immunosuppressants in 
vivo and could be helpful to optimize immunosuppressive therapy in transplanted 
patients. Additional monitoring of PD data of MPA such as AUC0-24 and Cmax may 
help to avoid side effects associated with over-immunosuppression (Shaw et al., 
2002).  
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4.4 Conclusion 
Synergistic effects on inhibition of lymphocyte function were observed for the 
combination of MPA plus CNI by blocking cells in the G0/G1 phase of the cell cycle, 
decreasing activation marker expression and NFAT-regulated gene expression. 
Adjustment of the MMF dosage by detection of the AUC0-24 may be required to avoid 
over-immunosuppression. FACS analysis and assessment of cytokine expression of 
PBMC represent important tools for monitoring and optimizing the 
immunosuppressive regimen within the transplant setting. 
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5 Summary 
  Complications of Calcineurin inhibitor (CNI), in particular nephrotoxicity, have a 
major effect on morbidity and mortality within the transplant setting.  We 
randomized liver transplant patients with renal dysfunction under CNI treatment to 
either a) receive mycophenolate mofetil (MMF) up to a dose fo 2 g/day followed by 
consecutive reduction of CNI (CNI reduction group) or b) to continue their current 
CNI dose (control group). Peripheral blood mononuclear cell (PBMC) were isolated 
from patient blood at baseline and after conversion to MMF/low dose CNI regimen. 
The expression of CD3, CD4, CD8 on PBMC and the expression of activation marker 
was determined by FACS analysis. In in vitro experiments freshly isolated PBMC 
from healthy volunteers were treated with mycophenolic acid (MPA) (1 up to 10 µM), 
cyclosporine A (CsA) (25-100 ng/mL), tacrolimus (Tac) (2-10 ng/mL) and combined 
CsA/MPA or Tac/MPA. T cell proliferation was measured by carboxfluorescein 
diacetate succinimidyl ester and FACS analysis.  T cell cycle analysis was performed 
by bromodexoxyuridine staining and FACS. Furthermore activation marker and 
nuclear factor of activated T cell (NFAT)-regulated cytokine expression was analyzed 
by FACS. The expression of cytokine mRNA was measured by real- time RT PCR. 
Combined MMF and low dose CNI therapy leads to reduction of percentages of CD8+ 
T cells, CD4+CD45RO+ T cells, CD3+CD56+ T cells and inhibition of activation 
marker expression. In vitro experiments have demonstrated that 1 µM MPA 
completely blocks the proliferation of CD4 and CD8 T cells. MPA stops the cell cycle 
of activated T cells at G0/G1 phase and this effect is dose-dependent. Both MPA and 
CNI inhibit the expression of activation T cell markers and this effect is potentiated by 
combined exposure to MPA and CNI. MPA has no detectable effect on 
NFAT-regulated genes such as IL-2, IL-4, IFN-γ and their protein expression. Our 
results suggest that FACS analysis and assessment of cytokine expression of PBMC 
represent important tools for monitoring and optimizing the immunosuppressive 
regimen within the liver transplant setting.  Adjustment of the MMF dosage by 
detection of the AUC may be required to avoid over-immunosuppression. Combined 
MMF and low dose CNI exhibit anti-proliferative effects in T cells by a) blocking the 
S phase of the cell cycle, b) decreasing NFAT-regulated gene and activation marker 
expression. 
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7. Abbreviation 
7-AAD 7-amino-actinomycin D 
APCs antigen-presenting cells 
APC allophycocyanin 
AUC area-under-the concentration-time curve 
AZA azathioprine 
BCR B-cell receptor 
BrdU bromodexoxyuridine 
BSA bovine serum albumin 
CFSE carboxfluorescein diacetate succinimidyl ester 
Cmax maximal concentration 
CNI calcineurin inhibitor 
CsA cyclosporine A 
CTL cytotoxic T lymphocyte 
DEPC diethylpyrocarbonate 
DMSO dimethylsulfoxide 
ELISA enzyme-linked immunosorbent assay 
ET endothelin 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
FITC fluorescein isothiocyanate 
HLA human leucocyte antigen 
IFN interferon 
IL interleukine 
Imax maximal inhibition 
IMPDH inosine monophosphate dehydrogenase 
MHC major histocopatibility complex 
MMF mycophenolate mofetil 
MPA mycophenolic acid 
NFAT nuclear factor of activated T cell 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PD pharmacodynamic 
PE phycoerythrin 
PerCP-Cy5.5 peridinin chlorophyll protein-cyanin5.5 
ROC receiver operator characteristic 
mRNA messanger riboneucleic acid 
RT PCR reverse transcriptase polymerase chain reaction 
Tac tacrolimus 
TCR T-cell receptor 
Th cell helper T cell 
TNF  tumor necrosis factor  
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